


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1-33. (Canceled)

34. (Currently Amended) A method ~~according to claim 26~~ for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds having the general formula II:



wherein

R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from H, halogen, NO<sub>2</sub>, CN, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF<sub>3</sub>, OR18, SR18, OC<sub>1-6</sub> alkyl, OC<sub>2-6</sub> alkyl, NR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC<sub>1-6</sub> alkylaryl, OC<sub>1-6</sub> alkylheteroaryl, OC<sub>1-6</sub> alkylcycloalkyl, OC<sub>1-6</sub> cycloheteroalkyl, CO<sub>2</sub>R18, C<sub>1-6</sub> alkylCO<sub>2</sub>R18, CONR18R19, C<sub>1-6</sub> alkylCONR18R19, NR18R19, C<sub>1-6</sub> alkylNR18R19, NR20C<sub>1-6</sub> alkylNR18R19, C<sub>1-6</sub> alkylNR20C<sub>1-6</sub> alkylNR18R19, NR18COR19, C<sub>1-6</sub> alkylNR18COR19, C<sub>1-6</sub> alkylNR20CONR18R19, NR20CONR18R19, C<sub>1-6</sub> alkylNR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19;


R18, R19 are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub> alkyl aryl, C<sub>1-4</sub> alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C<sub>1-4</sub>alkyl;

R11, R12 are each independently selected from H, C<sub>1-4</sub> alkyl, halogen, OC<sub>1-4</sub> alkyl;

and wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

35. (Currently Amended) A method according to claim 27 for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds having the general formula II:



wherein

R1, R2, R3, R4, R5, R6, R7, R8, R10 are each independently selected from H, C<sub>1-4</sub> alkyl, OC<sub>1-4</sub> alkyl, CO<sub>2</sub>H, CN;

R11, R12 are each independently selected from H, C<sub>1-4</sub> alkyl;

R9 is independently selected from H, halogen, NO<sub>2</sub>, CN, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF<sub>3</sub>, OR18, SR18, OC<sub>1-6</sub> alkyl, OC<sub>2-6</sub> alkyl1NR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC<sub>1-6</sub> alkylaryl, OC<sub>1-6</sub> alkylheteroaryl, OC<sub>1-6</sub> alkylcycloalkyl, OC<sub>1-6</sub> cycloheteroalkyl, CO<sub>2</sub>R18, C<sub>1-6</sub> alkylCO<sub>2</sub>R18, CONR18R19, C<sub>1-6</sub> alkylCONR18R19, NR18R19, C<sub>1-6</sub> alkylNR18R19, NR20C<sub>1-6</sub> alkylNR18R19, C<sub>1-6</sub> alkyl1NR20C<sub>1-6</sub> alkylNR18R19, NR18COR19, C<sub>1-6</sub> alkylNR18COR19, C<sub>1-6</sub> alkyl1NR20CONR18R19, NR20CONR18R19, C<sub>1-6</sub> alkyl1NR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19;

R18, R19 are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub> alkyl aryl, C<sub>1-4</sub> alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O,

S, NR21;

R20, R21 are each independently selected from H, C<sub>1-4</sub>alkyl;


wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

36. (Cancelled)

37. (Cancelled)

38. (Currently Amended) A method ~~according to claim 30~~ for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions comprising:

(a) one or more compounds having the general formula II:



wherein

R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from H, halogen, NO<sub>2</sub>, CN, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF<sub>3</sub>, OR18, SR18, OC<sub>1-6</sub> alkyl, OC<sub>2-6</sub> alkyl, NR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC<sub>1-6</sub> alkylaryl, OC<sub>1-6</sub> alkylheteroaryl, OC<sub>1-6</sub> alkylcycloalkyl, OC<sub>1-6</sub> cycloheteroalkyl, CO<sub>2</sub>R18, C<sub>1-6</sub> alkylCO<sub>2</sub>R18, CONR18R19, C<sub>1-6</sub> alkylCONR18R19, NR18R19, C<sub>1-6</sub> alkylNR18R19, NR20C<sub>1-6</sub> alkylNR18R19, C<sub>1-6</sub> alkylNR20C<sub>1-6</sub> alkylNR18R19, NR18COR19, C<sub>1-6</sub> alkylNR18COR19, C<sub>1-6</sub> alkylNR20CONR18R19, NR20CONR18R19, C<sub>1-6</sub> alkylNR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19;

R18, R19 are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub> alkyl aryl, C<sub>1-4</sub> alkyl heteroaryl, or may be joined to form an

optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR<sub>21</sub>;

R<sub>20</sub>, R<sub>21</sub> are each independently selected from H, C<sub>1-4</sub>alkyl;


R<sub>11</sub>, R<sub>12</sub> are each independently selected from H, C<sub>1-4</sub> alkyl, halogen, OC<sub>1-4</sub> alkyl;

(b) a pharmaceutically acceptable diluent,

wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

39. (Currently Amended) A method according to claim 31 for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions comprising:

(a) one or more compounds having the general formula II:



wherein

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>10</sub> are each independently selected from H, C<sub>1-4</sub> alkyl, OC<sub>1-4</sub> alkyl, CO<sub>2</sub>H, CN;

R<sub>11</sub>, R<sub>12</sub> are each independently selected from H, C<sub>1-4</sub> alkyl;

R<sub>9</sub> is independently selected from H, halogen, NO<sub>2</sub>, CN, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, aryl, heteroaryl, cylcoalkyl, cycloheteroalkyl, OCF<sub>3</sub>, OR<sub>18</sub>, SR<sub>18</sub>, OC<sub>1-6</sub> alkyl, OC<sub>2-6</sub> alkyl, NR<sub>18</sub>R<sub>19</sub>, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC<sub>1-6</sub> alkylaryl, OC<sub>1-6</sub> alkylheteroaryl, OC<sub>1-6</sub> alkylcycloalkyl, OC<sub>1-6</sub> cycloheteroalkyl, CO<sub>2</sub>R<sub>18</sub>, C<sub>1-6</sub> alkylCO<sub>2</sub>R<sub>18</sub>, CONR<sub>18</sub>R<sub>19</sub>, C<sub>1-6</sub> alkylCONR<sub>18</sub>R<sub>19</sub>, NR<sub>18</sub>R<sub>19</sub>, C<sub>1-6</sub> alkylNR<sub>18</sub>R<sub>19</sub>, NR<sub>20</sub>C<sub>1-6</sub> alkylNR<sub>18</sub>R<sub>19</sub>, C<sub>1-6</sub> alkylNR<sub>20</sub>C<sub>1-6</sub> alkylNR<sub>18</sub>R<sub>19</sub>, NR<sub>18</sub>COR<sub>19</sub>, C<sub>1-6</sub>

alkylNR18COR19, C<sub>1-6</sub>alkyl1NR20CONR18R19, NR20CONR18R19, C<sub>1-6</sub>alkyl1NR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19;

R18, R19 are each independently selected from H, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyl cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub>alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C<sub>1-4</sub>alkyl;

(b) a pharmaceutically acceptable diluent,

wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.